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Introduction
Although combinations of contraceptive pills had
been used in Britain as a method of post-coital
back-up since the 1960s, it was not until 1982 that
Schering PC4, a combined oestrogen-progestogen
product, was speciﬁcally licenced for emergency
post-coital contraception. It was another 20 years
again before emergency contraceptive pills in
their progestogen-only form were made available
to buy from behind the counter in pharmacies, fol-
lowing a consultation with a pharmacist. Today
women in the UK can obtain emergency contracep-
tion through a number of routes: via a prescription
from their General Practitioner (GP) or a sexual
health clinic, by purchasing it from a pharmacy,
and sometimes through an NHS scheme run
through their local pharmacy, in which case it
can be obtained free of charge.
Emergency hormonal contraception (EHC) is a
safe and effective way to protect against unplanned
pregnancy when contraception has not been used
or has failed. In the UK today, condoms and pills
remain the most popular methods of contracep-
tion. This is despite sustained attempts to promote
long-acting reversible contraceptives (LARCs) such
as the intrauterine device (IUD) and intrauterine
system (IUS), or the implant, Nexplanon. While
these may suit many women perfectly, others suffer
side-effects or simply feel they are not having sex
frequently enough to take on a long-acting form.
In this context, swift access to emergency contra-
ception should be seen as essential back-up to
women’s existing method, which women should
be encouraged to make use of when they need it.
While EHC will never be a silver bullet for
unintended pregnancy, it remains a signiﬁcantly
under-utilised resource.1 Only a third of women in
the UK report using EHC after an episode of unpro-
tected sex.2 EHC is extremely safe, even when used
repeatedly and within the same cycle. Repeat use
of EHC is classiﬁed as Level 1 in the World Health
Organization’s Medical Eligibility Criteria, indicating
there should be no restriction on use.3 However,
EHC was never embraced in the way it should
have been, nor its safety proﬁle emphasised. Indeed
the narrative around EHC as a manifestation of
moral malaise, and a marker of irresponsible
female sexuality that needs regulating, has paved
the way for the framework which places consider-
able barriers in women’s path when seeking to
obtain it in a timely fashion, and contributes to
women’s perception that this is a risky product
that should rarely be used.4
Twenty years ago, the WHO made clear that
“repeated use [of EHC] poses no health risks and
should never be cited as a reason for denying
women access to treatment”.5 Despite this, health
professionals are expected to discourage women
from use of EHC, not least by quick starting them
on “regular” options. EHC is not supposed to
replace routine hormonal contraception as the
lower dose daily pill is more effective at preventing
pregnancy on an ongoing basis, although this
raises questions as to why women should not be
“allowed” to choose a slightly less effective method
if they prefer it. However, the concern raised
around “abuse” of EHC means that it is not pro-
moted as a contraceptive option that women can
access easily when they need it.6
The price of the non-prescription retail product
was also deliberately set high to discourage women
from regular use. Despite a successful campaign by
PERSPECTIVE
1© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
the British Pregnancy Advisory Service (BPAS) in
2017 to reduce the cost of the progestogen pill
from as much as £30 to between £12 and £16
when sold in pharmacies, the price women pay
still remains extremely high in relation to the
actual cost of the pill and it is still only available
after consultation with a pharmacist. The product
remains behind the shelf, often out of eye-line,
with no in-store advertising of its availability.
While it is increasingly available online, the price
for timely delivery of a time-sensitive product is
extremely high. Although the pill is available for
free through prescription, if women do not meet
the criteria for the NHS-funded scheme in a phar-
macy this will require booking an appointment
with a GP or a clinic, which may have unusual
opening hours, or waiting at a walk-in service. As
time is of the essence with this product, these bar-
riers cause delay which puts women at greater risk
of unwanted pregnancy. Below, we share our per-
spective on the development of the narrative
around EHC in Britain and consider future paths
for a product that has been shamefully exceptiona-
lised and stigmatised.
Need, not choice
Today’s framing of “in emergencies only” is quite
different from the original intentions of those
involved in the post-coital pill development.
Early developments indicate manufacturers envi-
saged EHC would be made available to women
by choice and would become a suitable addition
to their arsenal of contraceptive options.7 The
ﬁrst EHC pill products were developed in the
early 1970s. Following the success and popularity
of the pill, testing for alternative hormonal con-
traceptive options continued. One of the objec-
tives of post-coital pill development was to
reduce drug exposure for women: growing fears
of thrombosis linked to the pill meant doctors
hoped to offer safer options for women who
were having sex less frequently. This may appear
as an outlandish construct given the EHC we
recognise today. Commonly we distinguish EHC
as a “back-up only” method. However, historically
EHC was developed as an additional method for
women having sporadic sex to take as a matter
of choice rather than need.
In fact, early manufacturers sought to provide
women with more than one dose to have at
home with a view to this being an ongoing method
for women having sex once a week or less.
Although never offered in the UK, Hungarian
pharmaceutical company Gedeon Richter initially
marketed a blister packet of 10 pills each contain-
ing 0.75 mg. Women were instructed to take two
per episode of unprotected sex, but this multiple-
use package came with the warning not to use
them more than four times per month.8 The num-
ber of pills made available to women was gradually
changed, apparently over concerns from the medi-
cal community that women were using it more
than four times per month.9 In 1994, the company
changed the presentation to a two-dose box, then
in 1998 to a one-time use package. Offering a post-
coital option for women to keep at home and use
when they choose to, differs drastically from the
framing around EHC today.
In the UK context, a number of debates have
surfaced in relation to EHC that indicate it has
been a contentious area of policy. Because of its
post-coital use, EHC has at times been positioned
as an abortion, adding to its stigma, with some reli-
gious groups arguing it should be subject to the
controls of the 1861 Offences Against the Person
Act for procuring a miscarriage. At the same
time, there were also concerns among some femin-
ists in the 1970s that EHC might undermine the call
for abortion on demand, and family planning
clinics were reluctant to advertise its availability
“for fear that the publicity would lead to a stream
of women thinking they could use it as a regular
contraceptive”.10 These arguments often over-
lapped with more socially conservative concerns
that EHC enabled sex without consequences; it
has been this aspect of the EHC debate, with the
pill symptomatic of recklessness and fecklessness,
which has largely dominated the tenor of media
coverage, at least until recently.
Despite this contentious history, there was sig-
niﬁcant public outrage when the UK’s leading
pharmacy chain, Boots, refused to reduce the
price of EHC in 2017 on the grounds that women
might “misuse” the product it if were more afford-
able. The company was eventually forced to back
down after intervention from MPs and a cascade
of negative media coverage.11 This indicates that
perceptions of EHC are starting to change, particu-
larly in a climate more sensitive to manifestations
of sexism and where women’s needs and perspec-
tives are given more attention. Nevertheless, the
continuing restrictions on access to EHC products,
including high cost and consultation, create a
vicious circle where the product appears irregular
and to require supervision, which in turn impacts
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upon the approach and attitudes of both health-
care professionals and women.
The early years of EHC in the UK set the tone for
the pill and meant the product was never presented
as simply a further contraceptive option for women.
In the UK, even when a dedicated product was devel-
oped, EHC marketing was risk-averse to satisfy the
growing concerns of policymakers around an after-
sex pill, rather than the needs of women. This
meant post-coital options were isolated as “abnor-
mal” and not positioned as an option for women
to choose, but as a pill they could avail themselves
of only when in need – with the clear message
that they should never in fact need to use it. This
takes us to the space we occupy today.
Changing the EHC record
Enabling emergency contraception to be sold
directly from the shelf without mandatory consul-
tation, as it is in Europe where comparable drug
classiﬁcations exist (e.g. Sweden, Netherlands and
Norway) and in North America, would be a key
step forward in normalising this product in the
UK. This would require a change in the classiﬁ-
cation, from a Pharmacy medicine (P) to a General
Sales List (GSL) medication, which can be sold in a
variety of locations. Products in this category in
the UK include a wide variety of painkillers, such
as paracetamol and ibuprofen, Nicotine Replace-
ment Therapies (NRTs) and strong indigestion reme-
dies such as esomeprazole, under the brand name
Nexium. All these products have considerably riskier
safety proﬁles than emergency contraception.12 In
the case of NRTs, the UK’s medicines licencing auth-
ority, the MHRA, deemed that any risk posed by
increasing public access to these drugs (they are
theoretically toxic to small children if consumed in
large quantities) was offset by the huge public
health beneﬁts of enabling more people to quit
smoking. There are no risks posed to any parties
by emergency contraception, and the health beneﬁts
for that individual woman of being able to avoid an
unwanted pregnancy are signiﬁcant.
Resistance to reclassiﬁcation has been put for-
ward by the Royal Pharmaceutical Society, which
wants to preserve the mandatory consultation on
the basis that it provides an important opportunity
to ensure women are taking the pill within the cor-
rect time frame, to discuss other methods of con-
traception, risk of sexual infections and address
any safeguarding concerns. Research shows, how-
ever, that most women presenting for emergency
contraception do so within the ﬁrst 24 hours, as
awareness that it should be taken as soon as poss-
ible is high;2 while a mystery shopper exercise con-
ducted by BPAS in 2018 discovered that few
pharmacies provided information about other
forms of contraception, or STI testing. As many
consultations took place in an open shop rather
than a private room, the likelihood of a woman
divulging issues relating to her safety was in any
event diminished.13 Regardless of whether this
assistance is provided by pharmacies, the position-
ing of a woman seeking emergency contraception
as being in need of information about “regular”
methods or being particularly at risk is a manifes-
tation of the stigmatisation of this product. No
such questioning is required when women pur-
chase condoms, sexual lubricants, or pregnancy
tests. The reclassiﬁcation of emergency contracep-
tion so it can be sold in the same way as these pro-
ducts is now a matter of urgency.
Greater attention must also be paid within NHS-
funded services to combating the stigma associated
with this product. Service providers are aware of
women’s concerns around “judgment”, the safety
of this method, and the need to explain why they
require EHC. Therefore, changes should be made
in service settings to pro-actively offer and encou-
rage this as a back-up option for women choosing
user-dependent methods, emphasising its safety,
and reducing the stigma attached to use.
In the longer term, licencing arrangements for
EHC should be changed so that the product could
be speciﬁcally prescribed for women who have
less frequent sex, as it was originally conceived,
as their ﬁrst-line contraceptive. We believe there
would be widespread interest in this; concerns
thus far expressed mainly centre on the effective-
ness as a regular method for irregular sex. Never-
theless, women are currently able to make their
choice from a range of options that vary in efﬁcacy
– from implants to diaphragms – so a pill that is
less effective than its daily counterpart should
not be discounted on that basis.
This change in approach would dramatically
alter the framing of and stigma attached to the
product, and allow it to take the place it deserves
on the menu of legitimate contraceptive options
that women can freely choose.
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